Pharma & Biotech VC & Investment News
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Today's issue
Refine Search
Biotechnology
Investment company eureKARE, which is focused on financing and building biotech companies in the disruptive fields of synthetic biology and the microbiome, has announced the emergence of eureKING. 12 May 2022
Biotechnology
US start-up biotech MOMA Therapeutics, which is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the completion of a $150 million Series B financing. 10 May 2022
Biotechnology
An Expert View from Mark Brewer, research director, Life Sciences, finnCap. 6 May 2022
Biotechnology
In a striking vote of confidence from big pharma, British targeted protein degradation (TPD) specialist Amphista Therapeutics has inked two strategic collaborations with major drug developers. 5 May 2022
Biotechnology
Tubulis, a Munich-based biotech company in the antibody drug conjugate (ADC) space, has announced the successful closing of a 60 million euros ($63 million) series B financing round. 4 May 2022
Biotechnology
Coming out of stealth since its founding in 2019, US biotech Dianthus Therapeutics today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company. 3 May 2022
Generics
India continues to establish itself as the pharmacy of the world as exports swell by 103% since 2013-14. The pharmaceutical industry is now being urged to work toward becoming the healthcare custodian of the world by adhering to good manufacturing practices, reports The Pharma Letter’s India correspondent. 3 May 2022
Pharmaceutical
British charity Cancer Research UK has launched a new project aimed at driving forward innovation in the development of oncology medicines. 28 April 2022
Biotechnology
Data and analytics company GlobalData has found that the UK has a thriving oncology-focused startup and venture capital (VC) scene compared to its European neighbors. 26 April 2022
Biotechnology
US biotech Apertura Gene Therapy today announced that it has launched with a Series A financing of up to $67 million from Deerfield Management Company to develop genetic medicines using platform technologies that address key limitations of genetic medicine delivery and expression. 26 April 2022
Biotechnology
UK biotech Forcefield Therapeutics has launched to develop drugs to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction. 25 April 2022
Pharmaceutical
Research from industry analyst GlobalData has highlighted the limited impact that Western sanctions have had on foreign innovator drugs in Russia. 22 April 2022
Biotechnology
US biotech firm Tessera Therapeutics, which is pioneering a new approach in genetic medicine known as GENE WRITING technology, has raised over $300 million in Series C financing. 21 April 2022
Biotechnology
USA-based Satellite Bio has emerged from stealth to reveal its ‘Tissue Therapeutics’ that are bioengineered to repair, restore or replace critical organ or tissue function. 20 April 2022
Pharmaceutical
Boston, USA-based Sionna Therapeutics, a life sciences company founded in 2019 to develop highly effective and differentiated treatments for cystic fibrosis (CF), has announced the official launch of the company and the closing of a $111 million Series B financing. 20 April 2022
Biotechnology
USA-based BioXcel Therapeutics, a biopharma using artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, has announced strategic financing agreements with funds managed by Oaktree Capital Management and Qatar Investment Authority (QIA). 19 April 2022
Biotechnology
In a filing with the US Securities and Exchange Commission (SEC), Boston-based rare disease specialist Imara has disclosed savage job cuts as part of an extensive restructuring. 19 April 2022
Biotechnology
USA-based Be Biopharma (“Be Bio”), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM) founded in October 2020, has announced the closing of a $130 million financing, bringing the total investment in the company to over $180 million. 14 April 2022
Biotechnology
Biotech funder and incubator Flagship Pioneering today announced that Michael Severino is joining the company as chief executive (CEO)-partner. 13 April 2022
Pharmaceutical
Anglo-Irish firm Poolbeg Pharma has announced that a number of new investors have expressed interest in acquiring up to £1.6 million ($2.1 million) in shares of the company which are currently locked-up and held in trust by Croft Nominees as a result of the distribution in specie from Open Orphan. 13 April 2022
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
San Diego-based Cidara Therapeutics, a biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has entered into a securities purchase agreement with certain investors to raise up to around $105 million. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides. 14 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Geron Corporation, a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat). 11 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Biotechnology
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
Pharmaceutical
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze